Results of Selective Intra-Arterial Infusions of Mesenchymal Stem Cells in Two Children with Rasmussen Encephalitis

Verónica Cantarín-Extremera1, Alfonso Friera2,3, África González-Murillo4,5, Gustavo J Melen4,5, Inmaculada de Prada-Vicente6, Maria C Fournier del Castillo6, Maria A Pérez-Jiménez2, María L Ruiz-Falcó-Rojas1 and Manuel Ramírez2,4

1Neuropediatrics, Hospital Universitario Niño Jesús, Madrid; Member of the Clinical Group linked (GCV14/ER/6) to the Networked Biomedical Research Centre for Rare Diseases (CIBERER), Carlos III Health Institute, Madrid, Spain
2Interventional Radiology, Hospital Universitario La Princesa, Madrid, Spain
3Instituto de Investigación Sanitaria La Princesa, Madrid, Spain
4Pediatric Hematology and Oncology, Advanced Therapies, Hospital Universitario Niño Jesús, Madrid, Spain
5Pathology, Hospital Universitario Niño Jesús, Madrid, Spain
6Neuropsychology, Hospital Universitario Niño Jesús, Madrid, Spain
7Neurophysiology, Hospital Universitario Niño Jesús, Madrid, Spain

Abstract

Aim: Rasmussen’s Encephalitis (RE) is a devastating pediatric syndrome. Patients receive different therapies, and eventually undergo functional hemispherectomy as the only treatment to achieve complete control of epileptic seizures. New therapies are needed to improve the prognosis of this rare disease. Since cytotoxic T lymphocytes have an active role in the pathogenic process of RE, we evaluated the feasibility of Mesenchymal Stem Cells (MSCs) for patients with RE based on the known immunomodulatory potential of these cells.

Methods: We present two patients with RE and refractory epilepsy. They were treated with antiepileptic drugs, steroids, immunoglobulins and plasmapheresis, but the epilepsy and cognitive deterioration did not stop. Both patients underwent a video-electroencephalographic record, complete laboratory tests, seizures diary and a neuropsychological testing prior to the first administration of MSC and after that. Bone-marrow-derived MSCs were culture expanded and prepared to study of the axis CXCR3 - CXC-chemokine ligand 10 (CXCL10) in MSCs chemotaxis. After confirming fulfillment the situation of the patients, 4 doses of MSCs, 3x106 cells each were administered targeting the affected hemisphere by selective intra-arterial infusion.

Results: The administrations were well-tolerated, and no adverse effects were seen after each infusion. A decrease in the frequency of generalized and focal seizure episodes was found in the first 2 weeks after each infusion. A significant improvement in Conners Continuous Performance Test was documented after the first infusion.

Conclusion: Though preliminary, this strategy appears to be safe and feasible in patients with RE. Given the transient improvement provided by short-lived MSCs, it could be a treatment option in acute deteriorations such a status epilepticus or repetitive seizures.

Keywords: Cellular therapy; Neuroinflammation; Rasmussen Encephalitis; Refractory epilepsy

Introduction

Rasmussen encephalitis (RE) is a rare devastating childhood disease characterized by intractable epilepsy, *epilepsia partialis continua*, progressive hemiparesis, and unilateral hemispheric atrophy with a clear cognitive deterioration that may appear before the onset of neurological symptoms. The progression of the symptoms to significant neurological impairment usually occurs within months to a few years. RE causes are unknown and no standardized medical treatment protocol currently exists for patients. Antiepileptic Drugs (AED) are not effective and despite data supporting a beneficial effect of early immunosuppressive and immunomodulatory interventions, surgery with hemispheric disconnection is the treatment of choice to try to avoid mental retardation, dementia, and death [1-3]. Therefore, new therapies are needed to improve the prognosis of this rare disease.

MSCs are a multipotent, non-hematopoietic class of progenitor cell that can be isolated from a variety of tissues, and are been investigated as a potential alternative therapeutic approach in degenerative and inflammatory disorders such as Crohn’s disease, Graft-versus-Host Disease (GvHD), Systemic Lupus Erythematosus (SLE), multiple sclerosis, fibrosis and arthritis [4,5]. The rationale for using MSCs in chronic intractable diseases of the Central Nervous System (CNS) partly relies on their ability to dampen inflammation, inhibit pathogenic immune responses, and release neuroprotective factors. Preclinical data show that MSC trophic properties and bioactive substances seem to effectively suppress neuroinflammation, decrease...
local lesions, and reduce the symptoms of neurological functional deficits and may slow or halt the development of irreversible disabilities [6-10].

Cytotoxic T lymphocytes have an active role in the pathogenic process of RE [11]. We have recently reported that the CXCR3-CXCL10 axis has a role in recruiting pathogenic T lymphocytes into the brains of these patients [12]. Based on their immunomodulatory properties and ability to respond to chemokine gradients, we have evaluated the feasibility of MSCs for patients with RE.

**Patient and Methods**

**Clinical cases**

**Patient 1**

A 12 years-old female was referred with the diagnosis of RE by Electroencephalogram (EEG), clinical and radiological criteria. She started two years earlier with partial seizures and was diagnosed of temporal lobe epilepsy. Seizures were not controlled with AEDs and steroids. *Epilepsia partialis continua* with focal to bilateral tonic-clonic episodes followed, developing light cognitive declination (Figure 1 (continuous line)). She showed an intellectual level below the mean (IQ = 70), with slight difficulties, and without significant discrepancies in all intellectual indices: Verbal Comprehension (VCI = 82), Perceptual Reasoning (PRI = 71), Working Memory (WMI = 75) and Processing Speed (PSI = 79). Alterations in some non-verbal skills (line orientation, nonverbal reasoning) and verbal tasks (recognition vocabulary, verbal comprehension and Word fluency / semantic association) were recorded. Alterations were also recorded in verbal and visual mnestic capacities (more acute the visual), in attentional processes and cognitive executive functions. In summar, both alterations associated with the functioning of the dominant hemisphere for language and non-dominant were recorded. The patient was left-handed, a Wada test showed complete dominance for the language of the left hemisphere. She suffered a left hemiparesis in the context of generalized epileptic seizures too. Monthly cycles of immunoglobulin and daily steroids were added to her pharmacological therapy with no success, the patient continued with focal and generalized secondary seizures daily or every other day. Based on the capacity of MSCs to modulate T-cell mediated autoimmune diseases, we proposed the use of autologous marrow-derived MSCs, targeting the affected hemisphere by selective intra-arterial infusion.

**Patient 2**

An 11 years-old female was referred to our hospital for re-evaluation of RE. She was diagnosed at 7 years-old as suffering Status Epilepticus (SE), focal, generalized epileptic seizure episodes, followed by *epilepsia partialis continua* with cognitive declination (Figure 1 (dashed line)). The patient showed an intellectual level within the average (IQ=84) with normal values in intellectual indices of Verbal Comprehension (VCI=91), Perceptual Reasoning (PRI=90) and Processing Speed (PSI=97), and slight difficulties in the index of Working Memory (WMI=97). She presented alterations in verbal tasks (verbal auditory processing and recognition vocabulary) and non-verbal skills (line orientation). The processes of abstract reasoning, memory, attention and executive functions were suitably preserved. As in the previous case, although with milder and less generalized difficulties, there are both alterations associated with the functioning of the dominant and non-dominant hemispheres. She was right-handed without family history of left-handed. The syndrome was catalogued as RE. She was treated with AED drugs, steroids, immunoglobulins and plasmapheresis, but the epilepsy and cognitive declination did not stop. She had a first time hemispherectomy surgery on March 2011 and second time on November 2011. Pathology studies of the biopsies confirmed a stage 1 in the first surgery and a stage 3 in the second one. The patient did not improve after surgery but continued with focal motor seizures every day and impaired awareness. She then received autologous marrow-derived MSCs, in a protocol like that of patient 1.

![Figure 1](image.jpg): Neuropsychological profile from our patients expressed in Z scores. Scores below -1 are considered as deficit (Patient 1 continuous line; Patient 2 dashed line).
and 1% penicillin–streptomycin (P/S, Gibco). The medium was replaced after 48 hours. Cells were maintained at 37°C and 5% CO2. MSC production complied with the principles of Good Manufacturing Practice (GMP) in an AEMPS-approved clean room.

**MSC administration**

Cell infusions were performed through selective internal carotid angiography of the affected hemisphere, using a transfemoral approach. We used a 4F catheter positioned in the cervical section of the internal carotid artery, and infused the cell suspension during 10 minutes. The catheter was retrieved after the procedure and the femoral access compressed. No complications were reported, neither neurological nor at the access point.

**Clinical assessment**

Both patients underwent a video-electroencephalographic record prior to the first administration of MSC as well as complete laboratory tests (blood count, coagulation, biochemistry including: hepatic, renal and ionic profile, and C reactive protein). A report of seizures was established daily, initiated after signing the informed consent and finishing after the last administration.

Each patient remained hospitalized for 24 hours to monitor the possibility of any acute adverse effect after MSC infusion. Upon discharge, the family was contacted by phone every 48 hours during the first week, and subsequently, once a week, to determine subacute or deferred adverse effects, and number of seizures, fever, headache or neurological symptoms different from the usual one. Blood tests were repeated and the seizure diary was checked once a month. A Conners Continuous Performance Test (CPT-3), computerized assessment of time perception to assess aspects of attention, was performed before the first MCS infusion, and twice afterwards by the patient 1.

**Pathology studies**

Brain material obtained after surgery of patient 1 who underwent hemispherectomy for treatment of Rasmussen encephalitis was fixed in 10% neutral formalin. Paraffin-embedded section were cut at 3 μm and stained for hematoxylin-eosin. Several polyclonal and monoclonal antibodies were used for immunohistochemical studies.

**Chemotaxis assay**

Human MSCs were placed in the upper chambers of 6.5 mm diameter 8 μm pore transwell systems (HTS Transwell-24 Well Plate, Corning, MA). The chemotactic stimulus in the lower chamber was human recombinant CXCL10/IP-10 (R&D Systems) at 100 ng/ml. The anti-CXCL10 (R&D Systems, 200 ng/ml) and anti-CXCR3 (R&D Systems, 200 ng/ml) antibodies served as control. All conditions were done in triplicates. Plates were incubated for 6 h at 37°C and 5% CO2. Migrating cells were stained with crystal violet and counted under microscopy. Results show Chemotaxis Units, an arbitrary measure of MSCs counted per microscopic field.

**Results**

**The axis CXCR3-CXCL10 in MSC chemotaxis**

T lymphocytes are recruited into the affected brain areas of RE patients through the CXCR3-CXCL10 axis. We tested whether human MSCs could respond to the same cue. We did standard transwell assays using primary human MSCs and found that these cells responded to the chemotactic gradient of human recombinant CXCL10 (Figure 2). The effect was abolished by means of inhibitory antiCXCL10 or antiCXCR3 antibodies. Therefore, human MSCs may target the damaged brain tissues of these patients through the same mechanisms that use pathogenic T lymphocytes [12].

**Clinical results**

**Patient 1**

After approval by the Spanish Medicine Agency, autologous MSCs were prepared under Good Manufacture Procedure conditions as explained elsewhere [12]. MSCs were infused through catheterization of the carotid right system (Figure 3). The patient received 4 doses of MSCs, 30×10⁶ cells each. The administrations were well tolerated, and no acute or long-term adverse effects were seen after infusions. A decrease in the frequency of generalized seizure episodes was found within the first 2 weeks after the first 2 administrations and the patient was seizure-free during 20 days for the first time in 2 years (Figure 4). The third dose was delayed, and we documented that the frequency of seizures returned to pre-MSC levels. A 3rd and a 4th doses were then provided, upon which generalized seizures decreased and eventually faded. The patients still had an epilepsy partialis continua. A CPT-3, computerized assessment of time perception to assess aspects of attention, was performed before the first MSC infusion, and twice afterwards. A significative improvement was documented after the first infusion, regaining pretherapy scores before the 3rd one (Figure 5). Five months after the first MSC infusion and one after the last one, the patient underwent epilepsy surgery. Histological analysis of the damage brain confirmed the typical findings corresponding to a stage 2 RE. No signs of tissue damage were found, nor could the presence of MSCs be demonstrated. The patient received a second surgery 7 months later, due to progressive disease.

**Patient 2**

The patient received 4 doses of MSCs (two administrations with a dosage of 30×10⁶ and two with 45×10⁶). The administrations were well tolerated, and no adverse effects were seen after infusions.
A complete control in the frequency of seizure episodes was found in the first 2 weeks after the first 2 infusions, reappearing afterwards (Figure 4B). A 3rd and 4th infusions did not have any effect, and the family decided to stop the treatment. She had a new surgery later. The anatomo-phatological study showed findings of stage 3-4 RE, with no signs of tissue damage related to the cellular therapy. A summary of the treatment protocol is shown in the figure 6.

Pathology studies

Patient 1 surgical specimen was studied after therapy and diagnosed as RE stage 2. In the cortex we found moderate chronic inflammation, with progression to panlaminar distribution: meninges, in superficial and deep neuronal layers of the cerebral cortex and white matter, with neuronophagia, decrease of neuronal population, activated microglia, reactive astrocytosis. Immunocytochemical studies, using astroglial and microglial markers, consistently demonstrated the concomitant presence of CD3, CD8 T lymphocytes and microglial reactions (CD68). NeuN positive neurons were significantly decreased.

Discussion

In this study, we present an initial dataset related to the safety and preliminary clinical efficacy of MSCs-based treatment for symptomatic RE, an example of immune-mediated epilepsy. RE typically affects previously normal children, causing severe deficits. There is no curative treatment for this disease. Although a number of promising medical treatments have emerged (tacrolimus, rituximab, natalizumab, adalimumab), none have yet been proven to control RE in the long term, nor provide adequate seizure relief to all patients [2,3,13,14]. Hemispherotomy, when possible, is widely considered to be only real ‘cure’ for RE, although at a high toll in terms of neurocognitive capacities for patients in their early years of life.

We tested MSCs for these patients based on the capacity of these cells to suppress immune-mediated tissue damages. The main pathological feature of RE is brain inflammation of one hemisphere, dominated by clones of cytotoxic CD8 T cells causing tissue damage [3]. Owens et al., reported findings of a pronounced Th1 response in the early symptomatic phase of the disease, with high levels of interferon-γ (IFN-γ) mRNA in RE brain tissue. IFN-γ induces the production of CXC-chemokine ligand 9 (CXCL9) by microglia, and of CXCL10 by microglia and astrocytes, and promotes IL-1-induced synthesis of CC-chemokine ligand 5 (CCL5) by astrocytes, which recruit T cells [15]. Further, IFN-γ has been shown to induce bursting of hippocampal pyramidal neurons in vitro, providing a possible link between T cells and epileptogenesis [16,17].
Microglia release of IL-1β in RE is critical for epileptogenic mechanisms [18]. Medicines that target all these mediators will have a positive impact on RE therapy.

Increasing information on the immunomodulatory capacities of human MSCs have provided grounds for their use in different diseases of immune origin [4,5]. In vivo studies involving the transplantation of MSCs into animals or humans with inflammatory diseases demonstrated strongly suppressive effects of MSCs on the activation and proliferation of T cells and on T cell-mediated inflammatory responses upon exposure to a combination of cytokines. MSCs activated by IFNγ combined with either Tumour Necrosis Factor (TNF) or IL-1 (proteins present in the ER environment), produce chemokines which recruit T cells to the proximity of MSCs. Subsequently, MSCs suppress the proliferation and activity of T cells in their vicinity by expressing Indoleamine 2,3-Dioxygenase (IDO). The immunosuppression by MSCs is also mediated by the production of cytokines that inhibit the proliferation and function of pro-inflammatory immune cells, such as T helper 1 (Th1) and/or Th17 cells, pro-inflammatory macrophages, neutrophils, NK cells and B cells, and enhance the numbers of anti-inflammatory immune cells, including anti-inflammatory macrophages, regulatory T cells and regulatory B cells. Anti-inflammatory immune cells can further suppress the activity and functions of pro-inflammatory immune cells and subsequently promote tissue repair [10,19-21]. In addition, MSCs inhibit microglial proliferation and their release of proinflammatory molecules. Combined to the immunomodulatory properties, it has also been proposed that MSCs recruit and stimulate local progenitor cells that eventually repair the damaged tissue [9,22]. In the brain, MSCs induce the release of neuroprotective molecules by microglia and increase their phagocytic capability through the release of soluble factors [10].

Figure 5: The results of patient 2 are presented in the Conners Continuous Performance Test (CPT-3). Evaluations performed with the same antiepileptic drugs. The first evaluation was before the first infusion. The second one was done a month later. In this, there was an improvement in the pattern associated with the disappearance of generalized seizures. In the third, the improvement disappears (reappearance of the seizures). In all three evaluations, the patient presented a continuous partial epilepsy.

Given the localized nature of RE and our previous experience with intra-arterial administration of MSCs within the brain vasculature [23], we chose this route to enhance the effects of the cell therapy. We did not have any acute adverse effect, evidencing that the procedure is feasible and repeated infusions are possible. Others have used the intravenous or the intrathecal routes for administration of MSCs in neurological diseases, with excellent safety profiles [7,10,24]. We did not find any side effects in the long-term follow up of these two patients, for as long as 5 years.

Figure 6: Summary of the treatment protocol.
The clinical outcome of the patients showed transient positive results with a decrease in the frequency of generalized seizures, and a seizure-free period for the first time in months of AED therapy. Moreover, patient 1 improved her CPT-3 scores after MSC infusion. The effects were not permanent, suggesting that MSCs did not persist and pointing to the half-life of the molecules secreted by the MSCs as responsible for the transient improvement. In the future, pre-conditioning, genetic and epigenetic manipulation of MSCs are key strategies to get better survival, proliferation and function of MSCs, increasing neuronal cell differentiation, immunomodulation, or other functions [25].

We did not find surviving MSCs in the brain tissues studied after surgery in patient 1, one month after the 4th MSCs infusion, supporting the clinical findings described and in accordance with previous reports on the lack of long-term engraftment and survival of administered human MSCs [26]. The images of multineucleated CD68 positive intravascular cells suggest phagocytoses of rests of MSCs by macrophages, which may explain the fate of infused MSCs. Patient 1 received MSCs earlier during her disease compared to patient 2 and had a better response in terms of seizure-free time after each of the various doses. It is tempting to speculate that the effectiveness of MSCs in RE may depend on stage of disease, preferably in the initial moments when more inflammation is present.

There are few trials of MSCs for treating patients with epilepsy, and none specifically for immune-mediated epilepsies. Hiebokazov et al., published a phase I open label study of 22 adults patients with refractory epilepsy secondary to infections, brain trauma or perinatal brain injury, treated with MSCs that were cultured under neurogenic differentiation inducing conditions [27].

To our knowledge, our experience is the first one on the use of MSCs in pediatric patients with RE. No major conclusion can be drawn from two clinical cases and only transient results but the safety of the procedure may be underscored. Our experience warrant further studies in the setting of a clinical trial.

Author’s Contribution

All authors have contributed to this manuscript, reviewed and approved the current form of the manuscript to be submitted. All authors take full responsibility for the data, the analyses and interpretation, and the conduct of the research; full access to all of the data; and the right to publish any and all data.

Conflict of Interest

None of the authors has any conflict of interest to disclose.

References


Submit Your Manuscript: https://www.heraldopenaccess.us/submit-manuscript